A Registered Cohort Study on Spastic Paraplegia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Yi Lin, MD,PhD
- Phone Number: +13615039153
- Email: wanjinchen75@fjmu.edu.cn
Study Contact Backup
- Name: Wan-Jin Chen, MD,PhD
- Phone Number: +1386061359 +1386061359
- Email: wanjinchen75@fjmu.edu.cn
Study Locations
-
-
-
Fuzhou, China
- Recruiting
- First Affiliated Hospital Fujian Medical University
-
Principal Investigator:
- Wan-Jin Chen
-
Contact:
- Wan-Jian Chen, MD, PhD
- Email: wanjinchen75@fjmu.edu.cn
-
Sub-Investigator:
- Ning Wang
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with the clinical diagnosis of spastic paraplegia
- Clinical diagnosis of patients with spastic paraplegia
- Unrelated healthy controls
Exclusion Criteria:
- Decline to participate.
- There are serious interferences with individual participation and adherence to the research protocol, including but not limited to neurological, psychological, and/or medical conditions.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Spastic Paraplegia Rating Scale (SPRS)
Time Frame: 6 months
|
Disease severity will be assessed by application of the Spastic Paraplegia Rating Scale (SPRS), a clinical rating scale measuring disease severity in Hereditary Spastic Paraplegia (Schule et al.
Neurology 2006).
The SPRS contains 13 items, each ranging from 0 to 4 points.
The total score is calculated as the sum of all items, yielding a range for the total score between 0 and 52.
Hereby, higher SPRS total scores indicate more severe disease.
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Qiu YS, Zeng YH, Yuan RY, Ye ZX, Bi J, Lin XH, Chen YJ, Wang MW, Liu Y, Yao SB, Chen YK, Jiang JY, Lin Y, Lin X, Wang N, Fu Y, Chen WJ. Chinese patients with hereditary spastic paraplegias (HSPs): a protocol for a hospital-based cohort study. BMJ Open. 2022 Jan 11;12(1):e054011. doi: 10.1136/bmjopen-2021-054011.
- Lin Q, Liu Y, Ye Z, Hu J, Cai W, Weng Q, Chen WJ, Wang N, Cao D, Lin Y, Fu Y. Potential markers for sample size estimations in hereditary spastic paraplegia type 5. Orphanet J Rare Dis. 2021 Sep 19;16(1):391. doi: 10.1186/s13023-021-02014-w. Erratum In: Orphanet J Rare Dis. 2021 Oct 27;16(1):451.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MRCTA,ECFAH OF FMU[2019]194
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.